Sign inJoin waitlistJoin the waitlist

Hideho Okada

Professor · University of California (San Francisco) School of Medicine

Credentials: · · · ·

History

University of California (San Francisco) School of Medicine
Present

Neurological Surgery
Univ of California, San Francisco Sch of Med

Research

A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma
Science Translational Medicine · 2017 · 1,567 citations
Actively personalized vaccination trial for newly diagnosed glioblastoma
Nature · 2019 · 754 citations
Immunotherapy response assessment in neuro-oncology: a report of the RANO working group
Review · The Lancet Oncology · 2015 · First of 19 authors · Corresponding · 599 citations

Ian Pollack
42 papers
RH
Ronald Hamilton
14 papers
Michael Lotze
13 papers
Joanna Phillips
12 papers
Kotaro Sasaki
12 papers · 8 as a resident
JD
Jill Dusak
11 papers
RJ
Regina Jakacki
10 papers
Susan Chang
10 papers
AP
Ashok Panigrahy
7 papers
Mitchel Berger
7 papers
Shawn Hervey-Jumper
7 papers
Diego Carrera
6 papers · 1 as a resident

Grants

Preclinical Development of Breakthrough Immunotherapy for Brain Tumors
National Institute of Neurological Disorders and Stroke · R35
Contact PI · $943.3K · University of California, San Francisco
2026–2033
Brain Tumor SPORE Grant
National Cancer Institute · P50
Project lead · $2.1M · University of California, San Francisco
2002–2028
Advancing Treatment and Understanding of Immunotherapy in Glioblastoma
National Cancer Institute · U19
Project lead · $1.3M · University of California, San Francisco
2021–2026
Preclinical Development of Breakthrough Immunotherapy for Brain Tumors
National Institute of Neurological Disorders and Stroke · R35
Contact PI · $6M · University of California, San Francisco
2017–2025

Clinical trials

A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG)
Principal investigator · Terminated · Phase 1
Nicholas Butowski
2017–2022
Neo-adjuvant Evaluation of Glioma Lysate Vaccines in WHO Grade II Glioma
Principal investigator · Completed · Phase 1
Jennie Taylor
2016–2024
Genetically Modified Cells (KIND T Cells) for the Treatment of HLA-A*0201-Positive Patients With H3.3K27M-Mutated Glioma
Study chair · Terminated · Phase 1
University of California, San Francisco
2023–2026
H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas
Study chair · Completed · Phase 1, Phase 2
Sabine Mueller, MD, PhD
2016–2023